What we found on the web about Liraglutide
Liraglutide - Wikipedia, the free encyclopedia
Liraglutide (NN2211), marketed under the brand name Victoza, is a long-acting glucagon-like peptide-1 (GLP-1) analog that has been developed by Novo Nordisk for the treatment of ...
Glucagon-like peptide-1 - Wikipedia, the free encyclopedia
GLP-1 analogs : exenatide, liraglutide; Dipeptidyl peptidase-4; Sitagliptin ( a DPP4 inhibitor) References ^ "Diabetes and Intestinal Incretin Hormones: A New Therapeutic Paradigm" at ...
Diabetes - Will liraglutide be approved by the FDA?
On April 2 2009, the FDA had an Advisory Committee meeting to discuss Novo-Nordisk's application to sell their new diabetes drug, liraglutide. The FDA routine...
Liraglutide Lowers Blood Sugar And Weight In Type 2 Diabetes Patients
Liraglutide treatment leads to greater reductions in HbA1c when added to one oral antidiabetic drug (OAD) compared to adding another OAD, according to two new medical publications ...
Medical News: Investigational Liraglutide Improves Outcomes as Oral ...
HARZ, Germany -- Diabetes outcomes may improve more by combining the oral experimental incretin mimetic liraglutide with metformin than by using oral glimepiride (Amaryl) as a ...
Glucagon.com
Lead-1 Add oN To SU Liraglutide vs rosiglitazone . Liraglutide (0.6-1.8 mg) or rosiglitazone 4 mg/day or placebo (n = 114) was added to patients receiving background therapy with ...
New Diabetes Drug Liraglutide Works
Sept. 24, 2008 -- Liraglutide, a new drug in the same class as Byetta , cuts blood sugar and lowers weight in a yearlong study of people with early type 2 diabetes . The FDA has ...
Novo Nordisk Reports Results From Liraglutide Study
Danish drugmaker Novo Nordisk’s final Phase III study of liraglutide, the once-daily human GLP-1 analogue for treatment of Type 2 diabetes, demonstrated favorable blood ...
Liraglutide, a once-daily human GLP-1 analogue, im...[Diabet Med. 2008 ...
PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to ...
Rapid Update on Inhibitors NovoSeven® RT Certification
Rapid Update on Inhibitors NovoSeven ® RT Certification This program will cover hemophilia A or B with inhibitors disease state education, as well as provide an overview of ...
Glucagon.com
Arg(34)Lys(26)-(N- epsilon -(gamma-Glu(N-alpha-hexadecanoyl))-GLP-1(7-37) Liraglutide (Victoza) , a long-acting DPP-4-resistant GLP-1 R agonist, has been developed ...
Liraglutide once a day versus exenatide twice a day for type 2 ...
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). By - Prof John B Buse MD ...
Liraglutide New Drug Application
Liraglutide is a new drug in development for the treatment of type 2 diabetes. Liraglutide information includes news, clinical trial results and side effects.
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Liraglutide

Liraglutide (NN2211), marketed under the brand name Victoza, is a long-acting glucagon-like peptide-1 (GLP-1) analog that has been developed by Novo Nordisk for the treatment of type 2 diabetes. The product was approved by the European Medicines Agency (EMEA) on July 3, 2009, and is still pending U.S. Food and Drug Administration (FDA) approval.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Liraglutide
Diabetes drug 'more effective' in weight loss
Presstv
Compared to commonly used obesity medication, a diabetes injection is more effective in promoting weight loss, a new study finds. According to the study published in The Lancet , diabetic patients receiving liraglutide (Victoza) are twice m...
New Study Results Show That Patients Have Higher Treatment ...
PressePortal.de
1) Liraglutide's positive effect on lipid profile in patients with type 2 diabetes[2] and 2) liraglutide's ability to lower both HbA1C and weight without inducing hypoglycaemia versus that of the other active comparators in the LEAD(TM) pro...
liraglutide Outperforms Alli in Weight Loss Study
dbtechno.com
Boston (DbTechNo) - Results of a new study show that the diabetes drug liraglutide promotes weight loss in obese patients better than orlistat. Orlistat is the name of a drug designed specifically for weight loss, thus this study finding is...
Diabetes drug may also help in weight loss
Los Angeles Times
A medication that is under review by the Food and Drug Administration for the treatment of type 2 diabetes may also promote weight loss, according to a study published online Thursday in the Lancet. The drug, liraglutide, was approved earli...
Experimental drug for type 2 diabetes may also help with weight loss
KCBD
LUBBOCK, TX (KCBD) - An experimental drug to treat type 2 diabetes may also help with weight loss. In a Danish study of more than 500 obese adults, those who took Liraglutide for five months lost about 15 pounds, compared to an average of 6...
Diabetes drug liraglutide 'better than orlistat and placebo for weight ...
Pulse
A daily injection with liraglutide – the latest incretin drug for diabetes - is better at promoting weight loss than orlistat and placebo, alongside diet and exercise, a new study has found. The drug was the second incretin mimetic to be la...
Study: Diabetes drug, liraglutide, may promote weight loss
TopNews United States
Going by the findings of a study published in the online Thursday-edition of the Lancet, the injected diabetes medication, liraglutide, manufactured by the Danish company Novo Nordisk, may also promote weight loss in obese people. Liragluti...